医学
封锁
肺癌
免疫检查点
免疫疗法
PD-L1
肿瘤科
癌症
内科学
免疫学
受体
作者
Song Gao,Jiaqian Wang,Zhongzheng Zhu,Junwei Fang,Yu Zhao,Zhuqing Liu,Huanlong Qin,Yuquan Wei,Huan Xu,Xu Dan,Li Yang,Qing Xu
出处
期刊:Immunotherapy
[Future Medicine]
日期:2023-02-01
卷期号:15 (2): 57-69
被引量:2
标识
DOI:10.2217/imt-2021-0339
摘要
Background: Although significant progress has been made in immune checkpoint inhibitor (ICI) treatment of advanced squamous cell carcinoma (SqCC), most patients still experience acquired drug resistance. Methods: We used a dendritic cell-based neoantigen vaccine combined with ICIs to treat advanced SqCC in a PD-1 blockade-resistant patient. Results: The follow-up of this patient after 12 months revealed significant tumor regression. We also identified a new JAK1 ICI-resistant mutation that could become a potential universal neoantigen target for tumor vaccines. Conclusion: Individualized management of advanced SqCC through a combined neoantigen vaccine and ICI administration could yield beneficial clinical outcomes. Vaccines targeting anti-PD-1-resistant JAK1 mutations might be of particular benefit to a specific group of solid tumor patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI